GLPwatch
Mounjaro for Opioid use disorder
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for opioid use disorder, and any use for this condition is off-label or investigational. Research linking tirzepatide to opioid use disorder is limited to a theoretical discussion of its potential as an anti-consumption agent in the context of addictions.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Opioid use disorder |
| Approval status | Investigational / off-label |
| Research papers | 1 |
Mounjaro is not FDA-approved for opioid use disorder; the research below reflects investigational or off-label study only.